Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025
Beta Bionics, Inc. (BBNX)
Company Research
Source: GlobeNewswire
IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2024 and introduced its annual guidance for the year ending December 31, 2025. Fourth Quarter 2024 Financial Highlights & Key Metrics Net sales of $20.4 million, up 145% compared to $8.4 million in the fourth quarter of 2023. Durable Medical Equipment (DME) channel net sales of $18.1 million, up 127% compared to $7.9 million in the fourth quarter of 2023.Pharmacy Benefit Plan (PBP) channel net sales of $2.4 million, up 491% compared to $0.4 million in the fourth quarter of 2023. Gross margin of 57.2%, down 344 basis points compared to 60.6% in the fourth quarter of 2023.Installed customer base (calculated as all new patient starts over a rolling four-year period) of 15,298 users, up 564% compared to 2,304 in the fourth quarter of 2023.4
Show less
Read more
Impact Snapshot
Event Time:
BBNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBNX alerts
High impacting Beta Bionics, Inc. news events
Weekly update
A roundup of the hottest topics
BBNX
News
- Beta Bionics (NASDAQ:BBNX) had its price target raised by analysts at Truist Financial Corporation from $32.00 to $37.00. They now have a "buy" rating on the stock.MarketBeat
- Beta Bionics (NASDAQ:BBNX) was given a new $28.00 price target on by analysts at Robert W. Baird.MarketBeat
- Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026GlobeNewswire
- Beta Bionics (NASDAQ:BBNX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Beta Bionics Announces Participation at Upcoming Investor ConferencesGlobeNewswire
BBNX
Earnings
- 10/28/25 - Beat
BBNX
Sec Filings
- 12/4/25 - Form 144
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- BBNX's page on the SEC website